Elutia (ELUT) Asset Writedowns and Impairment (2023 - 2024)

Elutia (ELUT) posted Asset Writedowns and Impairment of $209000.0 for Q4 2024, up 185.66% sequentially from -$244000.0 in Q3 2023.

Elutia (ELUT) Asset Writedowns and Impairment (2023 - 2024) Analysis & Trends

Elutia has reported Asset Writedowns and Impairment for 2 years, with the latest figure at $209000.0 in Q4 2024.

Quarterly Asset Writedowns and Impairment changed N/A year-over-year to $209000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was -$35000.0 (changed N/A YoY) and the FY2025 annual result came in at $458000.0, changed 0.43% from the prior year.
Asset Writedowns and Impairment climbed to $209000.0 in Q4 2024 per ELUT's latest filing, from -$244000.0 in the prior quarter.
Over five years, Asset Writedowns and Impairment peaked at $209000.0 in Q4 2024 and troughed at -$244000.0 in Q3 2023.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Abbott Laboratories	198.70 Bn	193.10 Bn	7.27 Bn
2	Stryker	125.85 Bn	122.37 Bn	4.50 Bn
3	Medtronic	118.44 Bn	109.22 Bn	6.41 Bn
4	Boston Scientific	72.64 Bn	72.10 Bn	3.85 Bn
5	Edwards Lifesciences	51.94 Bn	47.69 Bn	1.35 Bn
6	Dexcom	34.48 Bn	32.53 Bn	830.00 Mn
7	GE HealthCare Technologies	33.60 Bn	31.49 Bn	2.18 Bn
8	Koninklijke Philips	26.30 Bn	22.98 Bn	4.55 Bn
9	Steris	23.00 Bn	22.52 Bn	684.20 Mn
10	Elutia	39.87 Mn	19.98 Mn	1.45 Mn

Download Data